Fig. 1
From: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
Synovial tissue mRNA expression in peripheral spondyloarthritis. Effect of nilotinib and placebo treatment on in vivo synovial tissue mRNA expression in peripheral spondyloarthritis as assessed by quantitative polymerase chain reaction. The panel represents the transcription of c-Kit, interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF), and IL-23 before and after treatment with nilotinib (a–e) or placebo (f–j). The lines connect the data points for each patient between weeks (week) 0 and 12